Results for the quarter and year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Arunjyoti Bio Ventures Ltd approved audited financial results for the quarter and year ended 31 March 2025 at its meeting held on 29 May 2025. Full-year revenue from operations rose to ₹2,188.41 lakhs from ₹2,043.15 lakhs in FY24, while Q4 revenue fell sharply to ₹528.10 lakhs from ₹870.05 lakhs in Q4 FY24. The company reported a full-year loss after tax of ₹(182.15) lakhs versus ₹(34.89) lakhs in FY24. Statutory auditor V Ravi & Co issued an unmodified (unqualified) opinion, and the company also appointed K S Ramakrishna & Co as Internal Auditors and Manoj Parakh & Associates as Secretarial Auditors for the next term. A stock split from ₹10 to ₹1 face value was executed on 17 January 2025, and long-term borrowings were significantly reduced during the year.
Mixed for shareholders — the unqualified audit opinion and sharp reduction in long-term debt are positives, but the widening FY loss and steep Q4 revenue drop raise concerns about near-term profitability.